Financial
FY2025 revenue £63.3m (-5.1%).
Adjusted EBITDA £11.3m (from £15.8m); £21.6m cash, no debt.
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue £63.3m (-5.1%).
Adjusted EBITDA £11.3m (from £15.8m); £21.6m cash, no debt.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | £63.3m | -5.1% | — | — | Kooth |
Products not yet catalogued.
FY2025 revenue £63.3m (-5.1%).
Adjusted EBITDA £11.3m (from £15.8m); £21.6m cash, no debt.
Apr 2026: Kooth reported 2025 revenue of £63.3m (2024: £66.7m) and adjusted EBITDA of £11.3m (2024: £15.8m), citing currency movements, lower California product development revenue and a delayed Michigan contract. It reported no debt and £21.6m cash.
No data breaches, cyber incidents or regulator action involving Kooth found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
No product recalls, safety notices or clinical safety actions involving Kooth found in HSH's search of the last 24 months.
Apr 2026: Kooth said signing of its Michigan state contract was delayed, with revenue now expected in 2026. Its Soluna service in California had over 144,000 young people registered by end-2025.
No competitors linked yet.